Group 1 - The company Sinopharm (01801) announced the granting of stock options and restricted shares to a total of 1,374 participants, including directors, under the 2024 share plan [2] - Specifically, 1.9356 million stock options were granted to 66 participants, while 10.2413 million restricted shares were granted to 1,308 participants, pending acceptance by the grantees [2]

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The report highlights strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to further boost sales in 2026 [4][16] - Out-licensing revenue of RMB 957 million was recognized in FY25, with significant upfront payments from collaborations with Roche and Takeda expected to be progressively recognized in the financial statements from 2026 onward [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [7][19] - The early-stage pipeline shows strong global competitiveness, with 11 new molecules advanced into clinical development, expected to yield early data in 2026-2027 [9][20] - The target price is adjusted to HKD 107.40 based on a DCF model, reflecting an increase in revenue and net profit forecasts for 2026 and 2027 [10][21]

Core Insights - The article discusses the Phase II clinical trial results of the GLP-1/GCG dual receptor agonist, Ma Shidu (玛仕度肽), developed by Innovent Biologics, which showed significant weight loss and metabolic improvements in obese participants [4][5]. Group 1: Clinical Trial Results - The Phase II trial included 80 Chinese adult participants with obesity (BMI ≥ 30 kg/m²), with an average baseline weight of 96.9 kg [4]. - At week 24, the Ma Shidu 9 mg group achieved a weight loss of 15.4% compared to the placebo, with 81.7% of participants losing over 5%, 65.0% over 10%, and 21.7% over 20% [5]. - By week 48, weight loss increased to 18.6%, with 34.9% of participants losing over 20% of their body weight, equating to more than 30 pounds based on baseline weight [5]. Group 2: Metabolic Improvements - The study also reported improvements in various cardiovascular and metabolic indicators, including waist circumference, blood pressure, blood lipids, and uric acid levels [5]. - For participants with baseline liver fat content ≥ 5%, liver fat content decreased by 73.3% at week 24, with 83.3% of participants returning to normal liver fat levels [5]. Group 3: Safety Profile - The safety profile of Ma Shidu was favorable, with no serious adverse events reported and no participants discontinuing due to adverse reactions [5]. - The most common adverse effects were mild to moderate gastrointestinal symptoms, primarily occurring during the dose escalation phase [5]. Group 4: Regulatory and Development Status - Ma Shidu is a collaboration between Innovent Biologics and Eli Lilly, and it is expected to be approved in China for long-term weight management in overweight or obese adults by June 2025 [5]. - The Phase III clinical trial (GLORY-2) for the 9 mg dose has reached its primary endpoint, showing a weight reduction of 20.1%, and the related market application has been accepted [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][15] Core Insights - The company achieved total revenue of 13.042 billion HKD in 2025, representing a year-on-year growth of 38.4%. Product sales revenue reached 11.896 billion HKD, up 44.6% year-on-year. The company reported a net profit of 814 million HKD under IFRS, compared to a loss of 95 million HKD in 2024, and a Non-IFRS net profit of 1.723 billion HKD. This growth is attributed to the leading position in oncology products and rapid expansion in cardiovascular and metabolic product lines. The company has also entered a global strategic collaboration with Takeda Pharmaceutical, which will gradually confirm high upfront payments in the coming years. The profit forecasts for 2026-2027 have been raised, with expected net profits of 2.178 billion HKD, 2.504 billion HKD, and 2.960 billion HKD for 2026, 2027, and 2028 respectively, leading to a current price-to-earnings ratio of 77.0, 67.0, and 56.6 times [6][10]. Financial Summary - The company’s total revenue is projected to reach 18.515 billion HKD in 2026, with a year-on-year growth of 42.0%. The net profit is expected to increase to 2.178 billion HKD, reflecting a growth of 167.7% compared to 2025. The gross margin is anticipated to be 86.8%, and the net margin is expected to be 11.8% [10][12]. Global Expansion and Innovation - The company is accelerating its global layout, with multiple innovative pipelines entering global MRCT. The core product IBI363 has initiated a global MRCT Phase III clinical study for IO-resistant squamous NSCLC. IBI343 has received two BTD designations from NMPA and FTD from the FDA, with its first international Phase III study for third-line gastric cancer ongoing in China and Japan. IBI324 is expected to start an international Phase III clinical study in 2026 [7][8]. Future Product Pipeline - The next-generation pipeline focuses on oncology with IO+ADC technologies, including IBI363, IBI343, IBI3003, bispecific ADCs, and dual payload ADCs. These aim to enhance treatment standards or address unmet needs in various fields. Several pipelines are currently in international Phase I clinical studies [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved total revenue of 13.042 billion HKD in 2025, marking a year-on-year growth of 38.4%. Product sales revenue reached 11.896 billion HKD, up 44.6% year-on-year. The company reported a net profit of 814 million HKD under IFRS, compared to a loss of 95 million HKD in 2024. Non-IFRS net profit was 1.723 billion HKD. The growth is attributed to the company's leading position in oncology products and the rapid expansion of its cardiovascular and metabolic product lines [6][10] - The company has accelerated its globalization strategy, with key products entering global multi-regional clinical trials (MRCT). The core product IBI363 has initiated a global MRCT Phase III clinical study, while IBI343 has received breakthrough therapy designation (BTD) from NMPA and fast track designation (FTD) from the FDA [7][8] - The company has a strong pipeline focusing on innovative therapies in oncology, with multiple products expected to enter international Phase I clinical trials. The next-generation pipeline includes IBI363, IBI343, and others, aimed at addressing unmet medical needs [8] Financial Summary - In 2025, the company achieved a total revenue of 13.042 billion HKD, with a year-on-year growth of 38.4%. The projected revenues for 2026 and 2027 are 18.515 billion HKD and 21.515 billion HKD, respectively [10] - The net profit for 2026 is projected to be 2.178 billion HKD, with further growth expected in subsequent years, reaching 2.504 billion HKD in 2027 and 2.960 billion HKD in 2028 [10] - The company's gross margin is expected to remain high, with projections of 86.8% in 2026 and 86.6% in 2027 [10]

Core Viewpoint - Cinda Biologics is expected to report strong performance in the fiscal year 2025, achieving a net profit of 834 million yuan for the first time, with total revenue reaching 13 billion yuan, representing a year-on-year growth of 38% [1] Financial Performance - Total revenue for Cinda Biologics is projected to be 13 billion yuan, reflecting a year-on-year increase of 38% [1] - Product sales are anticipated to reach 11.9 billion yuan, marking a year-on-year growth of 45% [1] - The company is set to record its first annual net profit of 834 million yuan [1] Investment Outlook - The strong product line innovation capability and global development potential of Cinda Biologics support its transformation into a global biopharmaceutical company [1] - The investment rating for Cinda Biologics is maintained at "Buy," with the target price slightly increased from 110.62 HKD to 113.86 HKD [1]

Core Viewpoint - Cinda Biologics (01801.HK) is expected to report strong performance in the fiscal year 2025, achieving a net profit of 834 million RMB for the first time [1] Financial Performance - Total revenue reached 13 billion RMB, representing a year-on-year growth of 38% [1] - Product sales amounted to 11.9 billion RMB, reflecting a year-on-year increase of 45% [1] Investment Outlook - The company is recognized for its strong product innovation capabilities and global development potential, accelerating its transformation into a global biopharmaceutical player [1] - The investment rating for Cinda Biologics is maintained at "Buy," with the target price slightly increased from 110.62 HKD to 113.86 HKD [1]

Group 1 - The core announcement is that the company, Sinopharm (01801.HK), granted a total of 1,935,600 stock options to 66 grantees, including directors, under the 2024 share plan [1] - Additionally, the company awarded 10,241,300 restricted shares to 1,308 grantees, pending acceptance by the grantees [1]

Core Viewpoint - The company, Sinopharm (01801), announced the granting of stock options and restricted shares as part of its 2024 share plan, involving a total of 1,217,690 stock options and 10,241,300 restricted shares to various grantees, pending acceptance [1] Group 1 - The company granted 1,935,600 stock options to 66 grantees, including directors [1] - The company also granted 10,241,300 restricted shares to 1,308 grantees [1] - The grants are subject to acceptance by the grantees [1]

Core Insights - Innovent's partner Ollin Biosciences announced final data from the Phase 1b JADE clinical study, showing that OLN324 outperformed faricimab in treating diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) [1][9] Study Results - The JADE trial enrolled 164 patients, comparing OLN324 to faricimab, with all patients receiving three monthly doses followed by a 12-week follow-up [3][11] - At Week 20, OLN324 demonstrated greater retinal drying in DME patients compared to faricimab, with sustained vision gains [4][5] - In wAMD, OLN324 showed rapid and comparable improvements in retinal drying, with a mean visual acuity gain of +2.2 letters over faricimab at Week 20 [6][8] Safety Profile - OLN324 maintained a favorable safety profile, with no cases of intraocular inflammation, while faricimab had one case [7][9] Future Developments - Ollin and Innovent plan to advance OLN324 into global Phase 3 studies in DME and wAMD in 2026, targeting recruitment from multiple regions including North America, Europe, and Asia [9][12]